Mesenchymal Stem Cell-Based Therapy For Advanced Colorectal Cancer: Potential Mechanisms Of Therapy And Associated Risks

A. Hilland, V. Gallicchio
{"title":"Mesenchymal Stem Cell-Based Therapy For Advanced Colorectal Cancer: Potential Mechanisms Of Therapy And Associated Risks","authors":"A. Hilland, V. Gallicchio","doi":"10.52793/jscr.2021.2(2)-s4","DOIUrl":null,"url":null,"abstract":"Despite recent advances in diagnosis and treatment, colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths due to therapy resistance. Traditional treatment methods for colon cancer include surgery, chemotherapy, and radiation therapy. However, due to the unspecific target of these strategies and the presence of therapy-resistant colon cancer stem cells in the tumor microenvironment, nearly 50% of patients exhibit tumor recurrence. Therefore, there is an urgent need for alternative methods, and targeted cell-based therapies are emerging as promising agents for the treatment of heterogeneous malignancies. In particular, mesenchymal stem cells (MSCs) have been widely investigated for their therapeutic potential in regenerative medicine due to unique biological features, including self-regeneration and differentiation potential, tumor homing capacity, and immunomodulatory and paracrine functions. However, the exact role of MSCs in cancer treatment remains controversial as they have been shown to be involved in tumor progression and inhibition at the preclinical level. This review summarizes current findings on the application of MSCbased therapy for colon cancer, with a focus on the mechanisms of action of MSCs as therapeutic agents, including paracrine action, the capacity of migration, and impact on the regulation of the human immune system. It also discusses strategies to improve MSCs therapeutic effectiveness through genetic engineering and potential risks that should be considered before clinical use.","PeriodicalId":92258,"journal":{"name":"Journal of stem cell research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of stem cell research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52793/jscr.2021.2(2)-s4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Despite recent advances in diagnosis and treatment, colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths due to therapy resistance. Traditional treatment methods for colon cancer include surgery, chemotherapy, and radiation therapy. However, due to the unspecific target of these strategies and the presence of therapy-resistant colon cancer stem cells in the tumor microenvironment, nearly 50% of patients exhibit tumor recurrence. Therefore, there is an urgent need for alternative methods, and targeted cell-based therapies are emerging as promising agents for the treatment of heterogeneous malignancies. In particular, mesenchymal stem cells (MSCs) have been widely investigated for their therapeutic potential in regenerative medicine due to unique biological features, including self-regeneration and differentiation potential, tumor homing capacity, and immunomodulatory and paracrine functions. However, the exact role of MSCs in cancer treatment remains controversial as they have been shown to be involved in tumor progression and inhibition at the preclinical level. This review summarizes current findings on the application of MSCbased therapy for colon cancer, with a focus on the mechanisms of action of MSCs as therapeutic agents, including paracrine action, the capacity of migration, and impact on the regulation of the human immune system. It also discusses strategies to improve MSCs therapeutic effectiveness through genetic engineering and potential risks that should be considered before clinical use.
基于间充质干细胞的晚期结直肠癌治疗:潜在的治疗机制和相关风险
尽管最近在诊断和治疗方面取得了进展,但由于治疗耐药性,结直肠癌(CRC)仍然是癌症相关死亡的主要原因之一。结肠癌的传统治疗方法包括手术、化疗和放射治疗。然而,由于这些策略的非特异性靶点以及肿瘤微环境中存在治疗耐药结肠癌干细胞,近50%的患者出现肿瘤复发。因此,迫切需要替代方法,而靶向细胞治疗正在成为治疗异质性恶性肿瘤的有希望的药物。特别是,间充质干细胞(MSCs)由于其独特的生物学特性,包括自我再生和分化潜力、肿瘤归家能力、免疫调节和旁分泌功能,在再生医学中具有广泛的治疗潜力。然而,MSCs在癌症治疗中的确切作用仍然存在争议,因为它们已被证明在临床前水平参与肿瘤进展和抑制。本文综述了近年来以间充质干细胞为基础治疗结肠癌的研究进展,重点介绍了间充质干细胞作为治疗药物的作用机制,包括旁分泌作用、迁移能力以及对人体免疫系统调节的影响。本文还讨论了通过基因工程提高间充质干细胞治疗效果的策略以及临床应用前应考虑的潜在风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信